Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist
- 8 August 2017
- journal article
- research article
- Published by Taylor & Francis in The Aging Male
- Vol. 20 (4) , 250-256
Abstract
Background: The etiology of benign prostatic hyperplasia (BPH) has not been well established. The preferred medical treatment for many men with symptomatic benign prostatic hyperplasia is either an α-adrenergic receptor antagonist (α-blocker), or a 5α-reductase inhibitor. Single nucleotide polymorphism (SNP) is a powerful tool for successful implementation of individualized treatment. Methods: Eighteen SNPs associated with drug efficacy in a Chinese population were genotyped in 790 BPH cases (330 aggressive and 460 non-aggressive BPH cases) and 1008 controls. All BPH patients were treated with α-adrenergic blockers for at least 9 months. We tested the associations between tagging single nucleotide polymorphism and BPH risk/aggressiveness, clinical characteristics at baseline, including the International Prostate Symptom Score (IPSS) and total prostate volume, and changes in clinical characteristics after treatment. Results: There were nine SNPs associated with BPH risk, clinical progression and therapeutic effect. (1) There were nine tSNPs been chosen in CYP3A4, CYP3A5 and RANBP3L genes. (2) The SNP, rs16902947 in RANBP3L at 5p13.2 (p = .01), was significantly associated with BPH. (3) We found two SNPs, rs16902947 in RANBP3L at 5p13.2 (p = .0388) and rs4646437 in CYP3A4 at 7q21.1 (p = .0325), associated with drug effect. (4) Allele “G” for rs16902947 was found to be risk alleles for BPH risk (OR= 2.357, 95%CI 1.01–1.48). The “A” allele of rs4646437 was associated with lower IPSS at baseline (β= −0.4232, p= .03255). Conclusions: rs16902947, rs16902947 and rs4646437 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81570684)
- Shanghai Municipal Science and Technology Commission (14430720800, 15ZR1427600)
This publication has 44 references indexed in Scilit:
- Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasiaThe Aging Male, 2017
- The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional studyThe Aging Male, 2017
- The role of sex steroid hormones in benign prostatic hyperplasiaThe Aging Male, 2017
- Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostateThe Aging Male, 2015
- Etiology, Epidemiology, and Natural HistoryUrologic Clinics of North America, 2009
- Polymorphisms in the α 1A ‐adrenoceptor gene do not modify the short‐ and long‐term efficacy of α 1 ‐adrenoceptor antagonists in the treatment of benign prostatic hyperplasiaBJU International, 2006
- Modulation of the differentiation status of cultured prostatic smooth muscle cells by an ?1-adrenergic receptor antagonistThe Prostate, 1999
- Natural History of Prostatism: Relationship Among Symptoms, Prostate Volume and Peak Urinary Flow RateJournal of Urology, 1995
- Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community menUrology, 1994
- Growth of the Rat Prostate Gland is Facilitated by the Autonomic Nervous System1Biology of Reproduction, 1994